Searched for
PANKAJ R. PATEL
Indian pharma players can deliver 100 new drugs by 2047: Zydus ChairmanZydus Lifesciences Chairman Pankaj R Patel predicts that the Indian pharmaceutical industry can develop 100 new drugs by 2047 through enhan...- Innovation from India to empower people to lead healthier life: Zydus' Patel on selection for PadmaZydus Lifesciences Chairman Pankaj R Patel has been awarded the prestigious Padma Bhushan for his contributions to the lifesciences industr...
- Buy Zydus Lifesciences, target price Rs 470: JM FinancialZydus Lifesciences Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 42548.00 Crore) operating in Phar...
- IIM Ahmedabad appoints Pankaj Patel as new Chairperson of the Board of GovernorsThe Indian Institute of Ahmedabad (IIMA) has announced the appointment of Pankaj R. Patel as the new Chairperson of the its Board of Govern...
- Zydus Life's Pankaj Patel appointed part-time Non-official Director in Central Board, RBIThe Appointments Committee of the Cabinet (ACC) approved the proposal of appointment for a period of four years from the date of notificati...
- Hydroxychloroquine production scaled up: Zydus CadilaIndia manufactures 70% of the world's supply of hydroxychloroquine — Zydus and Ipca Labs being the two biggest players.
- CLSA retains buy on Cadila Healthcare, raises target price to Rs 330The brokerage has raised earnings estimates by 2-10% to reflect the strong earnings beat in the third quarter.
- Sell Cadila Healthcare, target Rs 220: Manas JaiswalSell Cadila Healthcare Ltd. at a price target of Rs 220.0 and a stoploss at Rs 241 from entry point.
- Sell Cadila Healthcare, target Rs 373: Dharmesh ShahSell Cadila Healthcare Ltd. at a price target of Rs 373.0 and a stop loss at Rs 402 from entry point.
- Buy Cadila Healthcare, target Rs 435: Manas JaiswalBuy Cadila Healthcare Ltd. at a price target of Rs 435.0 and a stop loss at Rs 419 from entry point.
- Sell Cadila Healthcare, target Rs 445: Manas JaiswalSell Cadila Healthcare at a price target of Rs 445 and a stop loss at Rs 470 from entry point.
- Pankaj Patel steps down as Cadila MD, son Sharvil to take overThe Board of Directors of Cadila Healthcare has unanimously approved the appointment of Sharvil P Patel as the Manging Director of the comp...
- Buy Cadila Healthcare, target Rs 540: Edelweiss Financial ServicesBuy Cadila Healthcare Ltd. at a price target of Rs 540.0 and a stop loss at Rs 453.0 from entry point
- Buy Cadila Healthcare, target Rs 480.0 : Dr CK NarayanBuy Cadila Healthcare Ltd. at a price target of Rs 480.0 and a stop loss at Rs 460.0 from entry point
- People complying with tax regime should be incentivised: Pankaj R Patel, Ficci presidentPeople who had deferred their spending would start doing it now. And also, we see severalstates releasing seventh pay commission awards.
- Rationalise taxes, simplify procedures in Budget: FICCIThe Budget for 2017-18 is scheduled to be presented by the Finance Minister on February 1.
- Pankaj Patel takes over as President of FICCIPatel brings with him over 35 years of professional experience and spearheads the affairs of Zydus Cadila, Federation of Indian Chambers of...
- US big market for Indian pharma cos despite FDA run-ins: Pankaj Patel, Zydus CadilaPatel says the US offers Indian drug firms bigger opportunities despite the latest run-ins with the FDA.
- Zydus launches diabetes treatment drug LipaglynPharmaceutical entity Zydus group on Monday said it has launched Lipaglyn, its patented new drug for treatment of diabetes.
- Zydus Cadila gets DCGI nod for launch of its NCE for diabetesCadila Healthcare today said Indian drug regulator has approved its new chemical entity, Lipaglyn to be used for treating a type of diabetes
Load More
